Young H. Im, Ph.D. - Publications

Affiliations: 
2007 Reformed Theological Seminary 
Area:
Cultural, Theology

89 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Lee YH, You CS, Jeong HC, Park M, Shim JH, Cho YW, Nahm KS, Im YH. Miniaturized measurement system of effective thermal conductivity for hydrogen storage materials Science of Advanced Materials. 8: 3-10. DOI: 10.1166/sam.2016.2588  0.48
2015 Lee JY, Park K, Lim SH, Kim HS, Yoo KH, Jung KS, Song HN, Hong M, Do IG, Ahn T, Lee SK, Bae SY, Kim SW, Lee JE, Nam SJ, ... ... Im YH, et al. Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer. Oncotarget. PMID 26527317 DOI: 10.18632/oncotarget.6192  0.4
2015 Park YH, Shin HT, Jung HH, Choi YL, Ahn T, Park K, Lee A, Do IG, Kim JY, Ahn JS, Park WY, Im YH. Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer. Oncotarget. PMID 26397225 DOI: 10.18632/oncotarget.5184  0.4
2015 Kang D, Kim IR, Im YH, Park YH, Ahn JS, Lee JE, Nam SJ, Park H, Kim E, Lee HK, Lee DY, Cho J. Quantitative changes in skin composition parameters due to chemotherapy in breast cancer patients: a cohort study. Breast Cancer Research and Treatment. 152: 675-82. PMID 26198993 DOI: 10.1007/s10549-015-3502-4  0.4
2015 Yu JI, Park W, Choi DH, Huh SJ, Nam SJ, Kim SW, Lee JE, Kil WH, Im YH, Ahn JS, Park YH, Cho EY. Clinical Outcomes and Prognostic Factors of Pathologic N3 Breast Cancer Treated With Modern Standard Treatments. Clinical Breast Cancer. PMID 26188791 DOI: 10.1016/j.clbc.2015.06.004  0.4
2015 Park K, Choi MK, Jung HH, Do IG, Lee KH, Ahn T, Kil WH, Kim SW, Lee JE, Nam SJ, Kim DH, Ahn JS, Im YH, Park YH. Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay. Oncotarget. PMID 26009992 DOI: 10.18632/oncotarget.4119  0.4
2015 Hong JY, Park YH, Choi MK, Jung HA, Lee SJ, Ahn JS, Im YH. Characterization of Durable Responder for Capecitabine Monotherapy in Patients With Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer. Clinical Breast Cancer. PMID 25997855 DOI: 10.1016/j.clbc.2015.04.004  0.4
2015 Yu JI, Park W, Choi DH, Huh SJ, Nam SJ, Kim SW, Lee JE, Kil WH, Im YH, Ahn JS, Park YH, Cho EY. Prognostic Modeling in Pathologic N1 Breast Cancer Without Elective Nodal Irradiation After Current Standard Systemic Management. Clinical Breast Cancer. 15: e197-204. PMID 25957739 DOI: 10.1016/j.clbc.2015.03.006  0.4
2015 Yu JI, Choi DH, Huh SJ, Park W, Nam SJ, Kim SW, Lee JE, Kil WH, Im YH, Ahn JS, Park YH. Proportion and clinical outcomes of postoperative radiotherapy omission after breast-conserving surgery in women with breast cancer. Journal of Breast Cancer. 18: 50-6. PMID 25834611 DOI: 10.4048/jbc.2015.18.1.50  0.4
2015 Lee JY, Lim SH, Lee MY, Kim H, Kim M, Kim S, Jung HA, Sohn I, Gil WH, Lee JE, Kim SW, Nam SJ, Ahn JS, Im YH, Park YH. Impact on Survival of Regular Postoperative Surveillance for Patients with Early Breast Cancer. Cancer Research and Treatment : Official Journal of Korean Cancer Association. PMID 25622590 DOI: 10.4143/crt.2014.168  0.4
2015 Park YH, Jung HH, Do IG, Cho EY, Sohn I, Jung SH, Kil WH, Kim SW, Lee JE, Nam SJ, Ahn JS, Im YH. A seven-gene signature can predict distant recurrence in patients with triple-negative breast cancers who receive adjuvant chemotherapy following surgery. International Journal of Cancer. Journal International Du Cancer. 136: 1976-84. PMID 25537444 DOI: 10.1002/ijc.29233  0.4
2015 Hyun SH, Ahn HK, Park YH, Im YH, Kil WH, Lee JE, Nam SJ, Cho EY, Choi JY. Volume-based metabolic tumor response to neoadjuvant chemotherapy is associated with an increased risk of recurrence in breast cancer. Radiology. 275: 235-44. PMID 25496075 DOI: 10.1148/radiol.14141129  0.4
2015 Jung HA, Park YH, Kim M, Kim S, Chang WJ, Choi MK, Hong JY, Kim SW, Kil WH, Lee JE, Nam SJ, Ahn JS, Im YH. Prognostic relevance of biological subtype overrides that of TNM staging in breast cancer: discordance between stage and biology. Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine. 36: 1073-9. PMID 25326808 DOI: 10.1007/s13277-014-2730-2  0.4
2015 Kim SY, Lee S, Jo S, Im YH, Lee HS. Microwave plasma carbonization for the fabrication of polyacrylonitrile-based carbon fiber Polymer (United Kingdom). 56: 590-595. DOI: 10.1016/j.polymer.2014.11.034  0.48
2014 Chang O, Choi EK, Kim IR, Nam SJ, Lee JE, Lee SK, Im YH, Park YH, Cho J. Association between socioeconomic status and altered appearance distress, body image, and quality of life among breast cancer patients. Asian Pacific Journal of Cancer Prevention : Apjcp. 15: 8607-12. PMID 25374176 DOI: 10.7314/APJCP.2014.15.20.8607  0.4
2014 Choi MK, Park YH, Kil WH, Lee JE, Nam SJ, Ahn JS, Im YH. Clinicopathological features of early failure of neoadjuvant chemotherapy in locally advanced breast cancer. Cancer Chemotherapy and Pharmacology. 74: 521-9. PMID 25047725 DOI: 10.1007/s00280-014-2542-5  0.4
2014 Park YH, Im SA, Cho EY, Ahn JH, Woo SY, Kim S, Keam B, Lee JE, Han W, Nam SJ, Park IA, Noh DY, Yang JH, Ahn JS, Im YH. Validation and comparison of CS-IHC4 scores with a nomogram to predict recurrence in hormone receptor-positive breast cancers. Oncology. 86: 279-88. PMID 24903080 DOI: 10.1159/000362281  0.4
2014 Swain SM, Im YH, Im SA, Chan V, Miles D, Knott A, Clark E, Ross G, Baselga J. Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA. The Oncologist. 19: 693-701. PMID 24869931 DOI: 10.1634/theoncologist.2014-0033  0.4
2014 Park LC, Jeong JY, Ji JH, Park S, Ahn JS, Im YH, Park YH. Intra-tumoral Metastatic Double Primary Carcinoma: Synchronous Metastatic Tumor in Lung from Breast and Thyroid Carcinoma. Cancer Research and Treatment : Official Journal of Korean Cancer Association. 46: 200-3. PMID 24851113 DOI: 10.4143/crt.2014.46.2.200  0.4
2014 Kim SB, Yoo C, Ro J, Im SA, Im YH, Kim JH, Ahn JH, Jung KH, Song HS, Kang SY, Park HS, Chung HC. Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline: randomized phase II multicenter trial. Investigational New Drugs. 32: 753-61. PMID 24715580 DOI: 10.1007/s10637-014-0093-6  0.4
2014 Swain SM, Baselga J, Miles D, Im YH, Quah C, Lee LF, Cortés J. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 25: 1116-21. PMID 24685829 DOI: 10.1093/annonc/mdu133  0.4
2014 Choi EK, Kim IR, Chang O, Kang D, Nam SJ, Lee JE, Lee SK, Im YH, Park YH, Yang JH, Cho J. Impact of chemotherapy-induced alopecia distress on body image, psychosocial well-being, and depression in breast cancer patients. Psycho-Oncology. 23: 1103-10. PMID 24664939 DOI: 10.1002/pon.3531  0.4
2014 Cho J, Choi EK, Kim IR, Im YH, Park YH, Lee S, Lee JE, Yang JH, Nam SJ. Development and validation of Chemotherapy-induced Alopecia Distress Scale (CADS) for breast cancer patients. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 25: 346-51. PMID 24379161 DOI: 10.1093/annonc/mdt476  0.4
2014 Lee SY, Im SA, Park YH, Woo SY, Kim S, Choi MK, Chang W, Ahn JS, Im YH. Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy. European Journal of Cancer (Oxford, England : 1990). 50: 698-705. PMID 24361227 DOI: 10.1016/j.ejca.2013.11.028  0.4
2014 Park YH, Jung HA, Choi MK, Chang W, Choi YL, Do IG, Ahn JS, Im YH. Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment. British Journal of Cancer. 110: 384-91. PMID 24346286 DOI: 10.1038/bjc.2013.757  0.4
2014 Jeong JH, Cho HW, Choi JY, Im YH, Jang SM. A comparative study on the exterior rotor BLDC motor according to the rotor permanent magnet shape Transactions of the Korean Institute of Electrical Engineers. 63: 237-244. DOI: 10.5370/KIEE.2014.63.2.237  0.32
2014 Shim JH, Park M, Lee YH, Kim S, Im YH, Suh JY, Cho YW. Effective thermal conductivity of MgH2 compacts containing expanded natural graphite under a hydrogen atmosphere International Journal of Hydrogen Energy. 39: 349-355. DOI: 10.1016/j.ijhydene.2013.09.092  0.48
2013 Kim H, Choi DH, Park W, Huh SJ, Nam SJ, Lee JE, Ahn JS, Im YH. Prognostic factors for survivals from first relapse in breast cancer patients: analysis of deceased patients. Radiation Oncology Journal. 31: 222-7. PMID 24501710 DOI: 10.3857/roj.2013.31.4.222  0.4
2013 Jung HA, Adenis A, Lee J, Park SH, Maeng CH, Park S, Ahn HK, Shim YM, Penel N, Im YH. Nomogram to predict treatment outcome of fluoropyrimidine/platinum-based chemotherapy in metastatic esophageal squamous cell carcinoma. Cancer Research and Treatment : Official Journal of Korean Cancer Association. 45: 285-94. PMID 24454001 DOI: 10.4143/crt.2013.45.4.285  0.4
2013 Jo KI, Im YH, Kong DS, Seol HJ, Nam DH, Lee JI. Gamma knife radiosurgery for brain metastases from breast cancer. Journal of Korean Neurosurgical Society. 54: 399-404. PMID 24379946 DOI: 10.3340/jkns.2013.54.5.399  0.4
2013 Park YH, Jung HH, Ahn JS, Im YH. Statin induces inhibition of triple negative breast cancer (TNBC) cells via PI3K pathway. Biochemical and Biophysical Research Communications. 439: 275-9. PMID 23973711 DOI: 10.1016/j.bbrc.2013.08.043  0.4
2013 Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, Steger GG, Suter TM, Toi M, Parmar M, Laeufle R, Im YH, Romieu G, Harvey V, Lipatov O, et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. The Lancet. Oncology. 14: 933-42. PMID 23932548 DOI: 10.1016/S1470-2045(13)70335-8  0.4
2013 Johnston SR, Kilburn LS, Ellis P, Dodwell D, Cameron D, Hayward L, Im YH, Braybrooke JP, Brunt AM, Cheung KL, Jyothirmayi R, Robinson A, Wardley AM, Wheatley D, Howell A, et al. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. The Lancet. Oncology. 14: 989-98. PMID 23902874 DOI: 10.1016/S1470-2045(13)70322-X  0.4
2013 Cortés J, Baselga J, Im YH, Im SA, Pivot X, Ross G, Clark E, Knott A, Swain SM. Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 24: 2630-5. PMID 23868905 DOI: 10.1093/annonc/mdt274  0.4
2013 Park KH, Sohn JH, Lee S, Park JH, Kang SY, Kim HY, Park IH, Park YH, Im YH, Lee HJ, Hong DS, Park S, Shin SH, Kwon HC, Seo JH. A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer. Investigational New Drugs. 31: 1300-6. PMID 23677653 DOI: 10.1007/s10637-013-9973-4  0.48
2013 Ahn HK, Park YH, Lee SJ, Park S, Maeng CH, Park W, Choi DH, Hur SJ, Ahn JS, Im YH. Clinical implication of Time To Brain Metastasis (TTBM) according to breast cancer subtypes. Springerplus. 2: 136. PMID 23667803 DOI: 10.1186/2193-1801-2-136  0.4
2013 Park YH, Jung KH, Im SA, Sohn JH, Ro J, Ahn JH, Kim SB, Nam BH, Oh do Y, Han SW, Lee S, Park IH, Lee KS, Kim JH, Kang SY, ... ... Im YH, et al. Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 1732-9. PMID 23569309 DOI: 10.1200/JCO.2012.45.2490  0.4
2013 Ko ES, Han BK, Kim RB, Ko EY, Shin JH, Hahn SY, Nam SJ, Lee JE, Lee SK, Im YH, Park YH. Analysis of factors that influence the accuracy of magnetic resonance imaging for predicting response after neoadjuvant chemotherapy in locally advanced breast cancer. Annals of Surgical Oncology. 20: 2562-8. PMID 23463090 DOI: 10.1245/s10434-013-2925-6  0.4
2013 Kim HR, Jung KH, Im SA, Im YH, Kang SY, Park KH, Lee S, Kim SB, Lee KH, Ahn JS, Kim SI, Sohn JH. Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905). Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 24: 1485-90. PMID 23380385 DOI: 10.1093/annonc/mds658  0.4
2013 Park SY, Lim SY, Um SW, Koh WJ, Chung MP, Kim H, Kwon OJ, Park HK, Kim SJ, Im YH, Ahn MJ, Suh GY. Outcome and predictors of mortality in patients requiring invasive mechanical ventilation due to acute respiratory failure while undergoing ambulatory chemotherapy for solid cancers. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 21: 1647-53. PMID 23314602 DOI: 10.1007/s00520-012-1709-z  0.4
2013 Lee S, Cho EY, Park YH, Ahn JS, Im YH. Prognostic impact of FOXP3 expression in triple-negative breast cancer. Acta Oncologica (Stockholm, Sweden). 52: 73-81. PMID 23075422 DOI: 10.3109/0284186X.2012.731520  0.4
2013 Im YH, Jang SM. Optimal design of interior permanent magnet synchronous machines consideration of magnet bh characteristic with different rotor type using response surface methodology Transactions of the Korean Institute of Electrical Engineers. 62: 1080-1089. DOI: 10.5370/KIEE.2013.62.8.1080  0.32
2013 Kang SB, Kim JJ, Im YH. An experimental investigation of a direct burning of crude Jatropha oil (CJO) and pitch in a commercial boiler system Renewable Energy. 54: 8-12. DOI: 10.1016/j.renene.2012.11.006  0.48
2013 Park M, Shim JH, Lee YS, Im YH, Cho YW. Mitigation of degradation in the dehydrogenation behavior of air-exposed MgH2 catalyzed with NbF5 Journal of Alloys and Compounds. 575: 393-398. DOI: 10.1016/j.jallcom.2013.05.210  0.48
2012 Bae SH, Park W, Huh SJ, Choi DH, Nam SJ, Im YH, Ahn JS. Radiation treatment in pathologic n0-n1 patients treated with neoadjuvant chemotherapy followed by surgery for locally advanced breast cancer. Journal of Breast Cancer. 15: 329-36. PMID 23091546 DOI: 10.4048/jbc.2012.15.3.329  0.4
2012 Ro J, Park S, Kim S, Kim TY, Im YH, Rha SY, Chung JS, Moon H, Santillana S. Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea. Bmc Cancer. 12: 322. PMID 22839200 DOI: 10.1186/1471-2407-12-322  0.4
2012 Ahn HK, Lee S, Park YH, Sohn JH, Jo JC, Ahn JH, Jung KH, Park S, Cho EY, Lee JI, Park W, Choi DH, Huh SJ, Ahn JS, Kim SB, ... Im YH, et al. Prediction of outcomes for patients with brain parenchymal metastases from breast cancer (BC): a new BC-specific prognostic model and a nomogram. Neuro-Oncology. 14: 1105-13. PMID 22693244 DOI: 10.1093/neuonc/nos137  0.4
2012 Park S, Ahn HK, Park LC, Hwang DW, Ji JH, Maeng CH, Cho SH, Lee JY, Park KT, Ahn JS, Park YH, Im YH. Implications of different CA 15-3 levels according to breast cancer subtype at initial diagnosis of recurrent or metastatic breast cancer. Oncology. 82: 180-7. PMID 22433564 DOI: 10.1159/000336081  0.4
2012 Ra HW, Kim JT, Khan R, Sharma D, Yook YG, Hahn YB, Park JH, Kim DG, Im YH. Robust and multifunctional nanosheath for chemical and biological nanodevices. Nano Letters. 12: 1891-7. PMID 22432910 DOI: 10.1021/nl204280d  0.48
2012 Kwon MJ, Park S, Choi JY, Oh E, Kim YJ, Park YH, Cho EY, Kwon MJ, Nam SJ, Im YH, Shin YK, Choi YL. Clinical significance of CD151 overexpression in subtypes of invasive breast cancer. British Journal of Cancer. 106: 923-30. PMID 22294188 DOI: 10.1038/bjc.2012.11  0.4
2012 Park YH, Im SA, Cho EY, Choi YL, Lee JE, Nam SJ, Yang JH, Ahn JS, Im YH. Small node-negative (T1b-cN0) invasive hormone receptor-positive breast cancers: is there a subpopulation that might have benefit from adjuvant chemotherapy? Breast Cancer Research and Treatment. 133: 247-55. PMID 22270935 DOI: 10.1007/s10549-012-1956-1  0.4
2012 Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. The Lancet. Oncology. 13: 25-32. PMID 22153890 DOI: 10.1016/S1470-2045(11)70336-9  0.4
2012 Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. The New England Journal of Medicine. 366: 109-19. PMID 22149875 DOI: 10.1056/NEJMoa1113216  0.4
2012 Im SA, Lee KS, Ro J, Lee ES, Kwon Y, Ahn JH, Ahn JS, Kim JH, Kang HS, Shin KH, Noh DY, Park IA, Kim SB, Im YH, Ha SW. Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: the Korean Cancer Study Group BR 07-01. Breast Cancer Research and Treatment. 132: 589-600. PMID 22094934 DOI: 10.1007/s10549-011-1852-0  0.4
2012 Im YH, Hwang SI, Jang SM, Choi JY, Choi JH. Analysis of torque pulsation considering interior permanent magnet rotor rib shape using response surface methodology Ieee Transactions On Magnetics. 48: 979-982. DOI: 10.1109/TMAG.2011.2176534  0.32
2012 Im YH, Yim SH, Kim JB. A web service for automated IP/SoC verification using computers on network Isocc 2012 - 2012 International Soc Design Conference. 398-401. DOI: 10.1109/ISOCC.2012.6407125  0.52
2012 Choi HS, Vaseem M, Kim SG, Im YH, Hahn YB. Growth of high aspect ratio ZnO nanorods by solution process: Effect of polyethyleneimine Journal of Solid State Chemistry. 189: 25-31. DOI: 10.1016/j.jssc.2011.12.008  0.48
2012 Chung M, Park C, Lee S, Park HC, Im YH, Chang Y. A decision support assessment of cogeneration plant for a community energy system in Korea Energy Policy. 47: 365-383. DOI: 10.1016/j.enpol.2012.05.002  0.48
2011 Kong JH, Park YH, Kim JA, Kim JH, Yun J, Sun JM, Won YW, Lee S, Kim ST, Cho EY, Ahn JS, Im YH. Patterns of skin and soft tissue metastases from breast cancer according to subtypes: relationship between EGFR overexpression and skin manifestations. Oncology. 81: 55-62. PMID 21934337 DOI: 10.1159/000331417  0.4
2011 Noh JM, Choi DH, Huh SJ, Park W, Yang JH, Nam SJ, Im YH, Ahn JS. Patterns of recurrence after breast-conserving treatment for early stage breast cancer by molecular subtype. Journal of Breast Cancer. 14: 46-51. PMID 21847394 DOI: 10.4048/jbc.2011.14.1.46  0.4
2011 Lee SJ, Park S, Ahn HK, Yi JH, Cho EY, Sun JM, Lee JE, Nam SJ, Yang JH, Park YH, Ahn JS, Im YH. Implications of bone-only metastases in breast cancer: favorable preference with excellent outcomes of hormone receptor positive breast cancer. Cancer Research and Treatment : Official Journal of Korean Cancer Association. 43: 89-95. PMID 21811424 DOI: 10.4143/crt.2011.43.2.89  0.4
2011 Lee S, Ahn HK, Park YH, Nam do H, Lee JI, Park W, Choi DH, Huh SJ, Park KT, Ahn JS, Im YH. Leptomeningeal metastases from breast cancer: intrinsic subtypes may affect unique clinical manifestations. Breast Cancer Research and Treatment. 129: 809-17. PMID 21785952 DOI: 10.1007/s10549-011-1682-0  0.4
2011 Park S, Jung HH, Park YH, Ahn JS, Im YH. ERK/MAPK pathways play critical roles in EGFR ligands-induced MMP1 expression. Biochemical and Biophysical Research Communications. 407: 680-6. PMID 21440529 DOI: 10.1016/j.bbrc.2011.03.075  0.4
2011 Yun J, Kim KH, Kang ES, Gwak GY, Choi MS, Lee JE, Nam SJ, Yang JH, Park YH, Ahn JS, Im YH. Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy. British Journal of Cancer. 104: 559-63. PMID 21285992 DOI: 10.1038/bjc.2011.4  0.4
2011 Park YH, Lee SJ, Cho EY, Choi YL, Lee JE, Nam SJ, Yang JH, Shin JH, Ko EY, Han BK, Ahn JS, Im YH. Clinical relevance of TNM staging system according to breast cancer subtypes. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 22: 1554-60. PMID 21242587 DOI: 10.1093/annonc/mdq617  0.4
2011 Lee SJ, Choi YL, Park YH, Kim ST, Cho EY, Ahn JS, Im YH. Thymidylate synthase and thymidine phosphorylase as predictive markers of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Cancer Chemotherapy and Pharmacology. 68: 743-51. PMID 21170649 DOI: 10.1007/s00280-010-1545-0  0.4
2011 Cho EY, Chang MH, Choi YL, Lee JE, Nam SJ, Yang JH, Park YH, Ahn JS, Im YH. Potential candidate biomarkers for heterogeneity in triple-negative breast cancer (TNBC). Cancer Chemotherapy and Pharmacology. 68: 753-61. PMID 21170648 DOI: 10.1007/s00280-010-1548-x  0.4
2011 Kim JE, Ahn JH, Jung KH, Kim SB, Kim HJ, Lee KS, Ro JS, Park YH, Ahn JS, Im YH, Im SA, Lee MH, Kim SY. Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01). Breast Cancer Research and Treatment. 125: 99-106. PMID 20922564 DOI: 10.1007/s10549-010-1201-8  0.4
2010 Yi SY, Ahn JS, Uhm JE, Lim do H, Ji SH, Jun HJ, Kim KH, Chang MH, Park MJ, Cho EY, Choi YL, Park YH, Im YH. Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotype. Bmc Cancer. 10: 527. PMID 20920367 DOI: 10.1186/1471-2407-10-527  0.4
2010 Choi YL, Oh E, Park S, Kim Y, Park YH, Song K, Cho EY, Hong YC, Choi JS, Lee JE, Kim JH, Nam SJ, Im YH, Yang JH, Shin YK. Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival. Bmc Cancer. 10: 507. PMID 20860845 DOI: 10.1186/1471-2407-10-507  0.4
2010 Lee S, Park YH, Kim KH, Cho EY, Ahn YC, Kim K, Shim YM, Ahn JS, Park K, Im YH. Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma. British Journal of Cancer. 103: 845-51. PMID 20700125 DOI: 10.1038/sj.bjc.6605831  0.4
2010 Jung HH, Park YH, Jun HJ, Kong J, Kim JH, Kim JA, Yun J, Sun JM, Won YW, Lee S, Kim ST, Ahn JS, Im YH. Matrix metalloproteinase-1 expression can be upregulated through mitogen-activated protein kinase pathway under the influence of human epidermal growth factor receptor 2 synergized with estrogen receptor. Molecular Cancer Research : McR. 8: 1037-47. PMID 20551150 DOI: 10.1158/1541-7786.MCR-09-0469  0.4
2010 Ra HW, Khan R, Kim JT, Kang BR, Im YH. The effect of grain boundaries inside the individual ZnO nanowires in gas sensing. Nanotechnology. 21: 85502. PMID 20101073 DOI: 10.1088/0957-4484/21/8/085502  0.48
2010 Jo SY, Kang BR, Kim JT, Ra HW, Im YH. The synthesis of single PdAu bimetallic nanowire: feasibility study for hydrogen sensing. Nanotechnology. 21: 055604. PMID 20023307 DOI: 10.1088/0957-4484/21/5/055604  0.48
2010 Park YH, Kim ST, Cho EY, Choi YL, Ok ON, Baek HJ, Lee JE, Nam SJ, Yang JH, Park W, Choi DH, Huh SJ, Ahn JS, Im YH. A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (< or = 1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment? Breast Cancer Research and Treatment. 119: 653-61. PMID 19957028 DOI: 10.1007/s10549-009-0665-x  0.4
2010 Park YH, Lee S, Cho EY, Choi YL, Lee JE, Nam SJ, Yang JH, Ahn JS, Im YH. Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status. Cancer Chemotherapy and Pharmacology. 66: 507-16. PMID 19956951 DOI: 10.1007/s00280-009-1190-7  0.4
2010 Choi JH, Lim HI, Lee SK, Kim WW, Kim SM, Cho E, Ko EY, Han BK, Park YH, Ahn JS, Im YH, Lee JE, Yang JH, Nam SJ. The role of PET CT to evaluate the response to neoadjuvant chemotherapy in advanced breast cancer: comparison with ultrasonography and magnetic resonance imaging. Journal of Surgical Oncology. 102: 392-7. PMID 19877158 DOI: 10.1002/jso.21424  0.4
2009 Kim HS, Park YH, Park MJ, Chang MH, Jun HJ, Kim KH, Ahn JS, Kang WK, Park K, Im YH. Clinical significance of a serum CA15-3 surge and the usefulness of CA15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer. Breast Cancer Research and Treatment. 118: 89-97. PMID 19322651 DOI: 10.1007/s10549-009-0377-2  0.4
2009 Park YH, Park MJ, Ji SH, Yi SY, Lim DH, Nam DH, Lee JI, Park W, Choi DH, Huh SJ, Ahn JS, Kang WK, Park K, Im YH. Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. British Journal of Cancer. 100: 894-900. PMID 19240719 DOI: 10.1038/sj.bjc.6604941  0.4
2009 Uhm JE, Park YH, Yi SY, Cho EY, Choi YL, Lee SJ, Park MJ, Lee SH, Jun HJ, Ahn JS, Kang WK, Park K, Im YH. Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy. International Journal of Cancer. Journal International Du Cancer. 124: 1457-62. PMID 19065658 DOI: 10.1002/ijc.24090  0.4
2009 Park BB, Uhm JE, Cho EY, Choi YL, Ji SH, Nam do H, Il Lee J, Park W, Huh SJ, Park YH, Ahn JS, Im YH. Prognostic factor analysis in patients with brain metastases from breast cancer: how can we improve the treatment outcomes? Cancer Chemotherapy and Pharmacology. 63: 627-33. PMID 18553084 DOI: 10.1007/s00280-008-0779-6  0.4
2008 Ra HW, Im YH. Effect of chemically reactive species on properties of ZnO nanowires exposed to oxygen and hydrogen plasma. Nanotechnology. 19: 485710. PMID 21836317 DOI: 10.1088/0957-4484/19/48/485710  0.68
2008 Park YH, Jung HH, Ahn JS, Im YH. Ets-1 upregulates HER2-induced MMP-1 expression in breast cancer cells. Biochemical and Biophysical Research Communications. 377: 389-94. PMID 18851945 DOI: 10.1016/j.bbrc.2008.09.135  0.4
2008 Ra HW, Choi KS, Kim JH, Hahn YB, Im YH. Fabrication of ZnO nanowires using nanoscale spacer lithography for gas sensors. Small (Weinheim An Der Bergstrasse, Germany). 4: 1105-9. PMID 18615418 DOI: 10.1002/smll.200700922  0.68
2008 Lee J, Im YH, Lee SH, Cho EY, Choi YL, Ko YH, Kim JH, Nam SJ, Kim HJ, Ahn JS, Park YS, Lim HY, Han BK, Yang JH. Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer. Cancer Chemotherapy and Pharmacology. 61: 569-77. PMID 17508214 DOI: 10.1007/s00280-007-0506-8  0.4
2007 Kim HJ, Im YH, Han BK, Choi N, Lee J, Kim JH, Choi YL, Ahn JS, Nam SJ, Park YS, Choe YH, Ko YH, Yang JH. Accuracy of MRI for estimating residual tumor size after neoadjuvant chemotherapy in locally advanced breast cancer: relation to response patterns on MRI. Acta Oncologica (Stockholm, Sweden). 46: 996-1003. PMID 17851879 DOI: 10.1080/02841860701373587  0.4
2006 Lee J, Jung HH, Im YH, Kim JH, Park JO, Kim K, Kim WS, Ahn JS, Jung CW, Park YS, Kang WK, Park K. Interferon-alpha resistance can be reversed by inhibition of IFN-alpha-induced COX-2 expression potentially via STAT1 activation in A549 cells. Oncology Reports. 15: 1541-9. PMID 16685393  0.4
2005 Umar A, Lee S, Im YH, Hahn YB. Flower-shaped ZnO nanostructures obtained by cyclic feeding chemical vapour deposition: structural and optical properties. Nanotechnology. 16: 2462-8. PMID 20818036 DOI: 10.1088/0957-4484/16/10/079  0.48
2005 Park BB, Kim WS, Lee J, Park KW, Kang JH, Lee SH, Park JO, Kim K, Jung CW, Park YS, Im YH, Kang WK, Ko YH, Lee MH, Park K. IMVP-16/Pd followed by high-dose chemotherapy and autologous stem cell transplantation as a salvage therapy for refractory or relapsed peripheral T-cell lymphomas. Leukemia & Lymphoma. 46: 1743-8. PMID 16263576 DOI: 10.1080/10428190500178266  0.4
Show low-probability matches.